The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada
- 229 Downloads
The total direct cost of screening and treating all human papillomavirus-related diseases (HPV-RD) has not been measured in a single study. Accurate cost estimates are needed to inform decisions on intervention priorities and evaluate the cost-effectiveness of existing programs. We used province-wide clinical, administrative, and accounting databases to measure direct medical costs of HPV infection in Manitoba (Canada).
All persons 9 years or older with health insurance coverage in Manitoba between April 2000 and March 2015 were eligible. We identified all persons with an incident HPV-RD and aggregated all medical costs (in 2014 Canadian dollars) related to that condition, including prescription drugs, diagnostic procedures, in-hospital and outpatient treatment, and physician visits.
We found that the median cost of treating a case of anogenital warts was $130. An episode of cervical dysplasia had a median cost of $220, compared to $1300 for an episode of cervical carcinoma in situ. The cost of treating HPV-related invasive cancer varied from $15,000 for cervical cancer to $33,000 for oral cavity cancer. Overall, 80% ($145 million) of the total cost was attributable to HPV infection. Cervical screening and follow-up accounted for $96 million (66%) of all costs and this cost component has declined following the introduction of new screening guidelines.
Overall, the average direct medical cost of HPV infection was $720 per newborn. The economic burden of HPV remains significant, although changes in cervical screening guidelines, prompted by the introduction of a public HPV vaccine program, appear to have promoted a promising trend towards lower costs.
The authors thank Dr. Randall Gieni for assistance with reviewing the literature relating to medical costs related to HPV-RDs. The authors acknowledge the Manitoba Centre for Health Policy for use of data contained in the Population Health Research Data Repository under project # 2016-025 (HIPC # 2015/2016-67; REB # HS19155 (H2015:431); RRIC #2016-028). The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, or other data providers is intended or should be inferred.
SM designed the study, GP and CR analyzed the data, CR and SM interpreted the data and drafted the manuscript. All authors revised the manuscript and approved the final version.
Compliance with Ethical Standards
Conflict of interest
SM has received unrestricted research grants from GlaxoSmithKline, Merck, Sanofi Pasteur, Pfizer, and Roche-Assurex for unrelated studies. CR and GP do not have any conflicts to report.
This work was supported by the Merck Investigator Studies Program with a grant to the International Centre for Infectious Diseases (ICID). SM is a Canada Research Chair in Pharmaco-epidemiology and Vaccine Evaluation. The sponsors had no role in the design or conduct of the study, including but not limited to, data identification, collection, management, analysis and interpretation, or preparation, review, or approval of the final results. The opinions presented in the report do not necessarily reflect those of the sponsors.
- 4.IARC Working Group. Human papillomaviruses. IARC Monographs on the evaluation of the carcinogenic risks to humans. Lyon: International Agency for Research on Cancer; 1995.Google Scholar
- 8.De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626–36. https://doi.org/10.1002/ijc.24116.CrossRefPubMedGoogle Scholar
- 11.CDC. Pinkbook: Human Papillomavirus Chapter—Epidemiology of Vaccine-Preventable Diseases. 2015. CDC—Pinkbook: Human Papillomavirus Chapter—Epidemiology of Vaccine-Preventable Diseases. 2015. http://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html. Accessed 06 April 2015.
- 17.Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30(42):6016–9. https://doi.org/10.1016/j.vaccine.2012.07.056.CrossRefPubMedGoogle Scholar
- 27.Canadian Cancer Statistics 2016. Toronto: Canadian Cancer Society’s Advisory Committee on Cancer Statistics; 2016. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2016-EN.pdf?la=en. Accessed 10 Oct 2017.
- 28.Finlayson GS, Ekuma O, Yogendran M, Burland E, Forget E. The Additional Cost of Chronic Disease in Manitoba. Winnipeg; 2010. https://www.researchgate.net/publication/275649026_Chronic_Disease_in_Manitoba_What_are_the_costs_Winnipeg_Manitoba_Centre_for_Health_Policy. Accessed 10 Aug 2017.
- 30.OECD. Health expenditure indicators. http://www.oecd-ilibrary.org/social-issues-migration-health/data/oecd-health-statistics/system-of-health-accounts-health-expenditure-by-function_data-00349-en. Accessed 4 Sept 2017.
- 33.de Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S, et al. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open. 2013;1(1):E1–8. https://doi.org/10.9778/cmajo.20120013.CrossRefPubMedGoogle Scholar
- 34.Cromwell I, Ferreira Z, Smith L, van der Hoek K, Ogilvie G, Coldman A et al. Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis. Curr Oncol (Tor Ont). 2016;23(Suppl 1):S14–S22. https://doi.org/10.3747/co.23.2914.
- 36.McCrory D, Matchar D, Bastian L, Datta S, Hasselblad V, Hickey J. Evaluation of cervical cytology. Evidence report/technology assessment No. 5. Rockville: Agency for Health Care Policy and Research; 1999.Google Scholar
- 40.Copeland G, Lake A, Firth R, Wohler B, Wu X-C, Schymura MJ et al. Cancer in North America: 2009-2013. Volume One: Combined Cancer Incidence for the United States, Canada and North America; 2016.Google Scholar